The distribution ofo,p′-DDD (Mitotane) among serum lipoproteins in normo- and hypertriglyceridemia
| Autor: | A. J. Moolenaar, E. A. van der Velde, J. A. Gevers Leuven, A. P. van Seters, D. O. E. Gebhardt |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Cancer Research
medicine.medical_specialty Severe hypertriglyceridemia Very low-density lipoprotein Chromatography Gas Time Factors Lipoproteins Toxicology Pharmacokinetics Reference Values Internal medicine Chylomicrons medicine Humans Distribution (pharmacology) Pharmacology (medical) Mitotane Hypertriglyceridemia Pharmacology Chemistry Carcinoma digestive oral and skin physiology nutritional and metabolic diseases equipment and supplies medicine.disease Adrenal Cortex Neoplasms Endocrinology Oncology lipids (amino acids peptides and proteins) Lipoprotein Chylomicron medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 29:331-334 |
| ISSN: | 1432-0843 0344-5704 |
| DOI: | 10.1007/bf00685956 |
| Popis: | We found that the distribution of the lipophilic chemotherapeutic agent o,p'-DDD (mitotane) among serum (lipo)proteins was altered in hypertriglyceridemia, with relatively more o,p'-DDD accumulating in the chylomicron and very-low-density lipoprotein (VLDL) fraction. Intralipid, an artificial chylomicron emulsion, or isolated VLDL could extract o,p'-DDD from the other serum (lipo)proteins. There was an inverse relationship between the relative amount of o,p'-DDD found in the fraction exhibiting a density of less than 1.006 g/ml (chylomicrons plus VLDL) and the relative amount observed in the LDL or HDL fractions of serum. Our results indicate that hypertriglyceridemia may impede the entry of o,p'-DDD into the brain or the adrenals. For therapeutic monitoring of o,p'-DDD levels in severe hypertriglyceridemia, we recommend that the chylomicron and VLDL fraction first be removed from the serum by ultracentrifugation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink